MeMed is an Israeli medtech company. MeMed has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity.
The CE marking in Europe indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. This certification is a prerequisite for the marketing of any product manufactured outside of the EU if it is to be permitted for sale within the EU.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
MeMed is a medtech and bio-convergence company that has developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. This includes testing for Covid-19.
Just when you thought that the world had reopened after the long Covid nightmare, things seem to have backslid now into another global shutdown. This is because the Delta variant has been proven to be much more virulent with a higher rate of morbidity than the original Coronavirus. Even the vaccinated can be affected, but at least the data shows that those vaccinated might get sick, but not so ill that it would be life-threatening.
So now countries like Israel are re-imposing Covid rules such as requiring masks in indoor public spaces. Israel is also requiring that all international travelers get tested both before and after their flights. So any and all new Covid tests that can be faster and more efficient are welcome news.
But the new MeMed test is different. This test checks to see the probability that someone might become seriously ill.
MeMed COVID-19 Severity is a host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes.
The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.
Eran Eden, MeMed’s co-founder and CEO, said: “I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation. MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics.
It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”
